Logo of jnmaLink to Publisher's site
J Natl Med Assoc. 2002 Oct; 94(10 Suppl): 1–26.
PMCID: PMC2594139

Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Valentine J. Burroughs, Randall W. Maxey, and Richard A. Levy
Author information ► Copyright and License information ►

Abstract

It is now well documented that substantial disparities exist in the quality and quantity of medical care received by minority Americans, especially those of African, Asian and Hispanic heritage. In addition, the special needs and responses to pharmaceutical treatment of these groups have been undervalued or ignored. This article reviews the genetic factors that underlie varying responses to medicines observed among different ethnic and racial groups. Pharmacogenetic research in the past few decades has uncovered significant differences among racial and ethnic groups in the metabolism, clinical effectiveness, and side-effect profiles of many clinically important drugs. These differences must be taken into account in the design of cost management policies such as formulary implementation, therapeutic substitution and step-care protocols. These programs should be broad and flexible enough to enable rational choices and individualized treatment for all patients, regardless of race or ethnic origin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (4.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 1
1
icon of scanned page 2
2
icon of scanned page 3
3
icon of scanned page 4
4
icon of scanned page 5
5
icon of scanned page 6
6
icon of scanned page 7
7
icon of scanned page 8
8
icon of scanned page 9
9
icon of scanned page 10
10
icon of scanned page 11
11
icon of scanned page 12
12
icon of scanned page 13
13
icon of scanned page 14
14
icon of scanned page 15
15
icon of scanned page 16
16
icon of scanned page 17
17
icon of scanned page 18
18
icon of scanned page 19
19
icon of scanned page 20
20
icon of scanned page 21
21
icon of scanned page 22
22
icon of scanned page 23
23
icon of scanned page 24
24
icon of scanned page 25
25
icon of scanned page 26
26
 

Images in this article

Figure 3
Figure 3
on p.11
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999 Oct 14;341(16):1198–1205. [PubMed]
  • Bernabei R, Gambassi G, Lapane K, Landi F, Gatsonis C, Dunlop R, Lipsitz L, Steel K, Mor V. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA. 1998 Jun 17;279(23):1877–1882. [PubMed]
  • Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994 Mar 17;330(11):763–768. [PubMed]
  • Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999 Jun 23;281(24):2305–2315. [PubMed]
  • Schneider EC, Leape LL, Weissman JS, Piana RN, Gatsonis C, Epstein AM. Racial differences in cardiac revascularization rates: does "overuse" explain higher rates among white patients? Ann Intern Med. 2001 Sep 4;135(5):328–337. [PubMed]
  • Freeman HP, Payne R. Racial injustice in health care. N Engl J Med. 2000 Apr 6;342(14):1045–1047. [PubMed]
  • Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang LL. "We don't carry that"--failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med. 2000 Apr 6;342(14):1023–1026. [PubMed]
  • Tai-Seale M, Freund D, LoSasso A. Racial disparities in service use among Medicaid beneficiaries after mandatory enrollment in managed care: a difference-in-differences approach. Inquiry. 2001 Spring;38(1):49–59. [PubMed]
  • Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000 May 17;283(19):2579–2584. [PubMed]
  • Rana BK, Hewett-Emmett D, Jin L, Chang BH, Sambuughin N, Lin M, Watkins S, Bamshad M, Jorde LB, Ramsay M, et al. High polymorphism at the human melanocortin 1 receptor locus. Genetics. 1999 Apr;151(4):1547–1557. [PMC free article] [PubMed]
  • Owens K, King MC. Genomic views of human history. Science. 1999 Oct 15;286(5439):451–453. [PubMed]
  • Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001 May 3;344(18):1392–1393. [PubMed]
  • Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000 Jun;25(3):197–220. [PubMed]
  • Vesell ES. The influence of host factors on drug response. I. Ethnic background. Ration Drug Ther. 1979 Aug;13(8):1–7. [PubMed]
  • Weber WW. Populations and genetic polymorphisms. Mol Diagn. 1999 Dec;4(4):299–307. [PubMed]
  • Luzzatto L, Notaro R. Malaria. Protecting against bad air. Science. 2001 Jul 20;293(5529):442–443. [PubMed]
  • Bech-Thomsen N, Angelo HR, Wulf HC. Skin pigmentation as a predictor of minimal phototoxic dose after oral methoxsalen. Arch Dermatol. 1994 Apr;130(4):464–468. [PubMed]
  • Kligman AM, Kaidbey KH. Phototoxicity to benoxaprofen. Eur J Rheumatol Inflamm. 1982;5(2):124–137. [PubMed]
  • Tseng C, Hoffman B, Kurimoto I, Shimizu T, Schmieder GJ, Taylor JR, Streilein JW. Analysis of effects of ultraviolet B radiation on induction of primary allergic reactions. J Invest Dermatol. 1992 Jun;98(6):871–875. [PubMed]
  • Kalow W. Pharmacoanthropology: outline, problems, and the nature of case histories. Fed Proc. 1984 May 15;43(8):2314–2318. [PubMed]
  • Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978 Feb;88(2):251–258. [PubMed]
  • Lawson WB. Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol Bull. 1996;32(2):275–281. [PubMed]
  • Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998 Sep 18;281(5384):1820–1821. [PubMed]
  • Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 Oct 15;286(5439):487–491. [PubMed]
  • Wolf CR, Smith G. Pharmacogenetics. Br Med Bull. 1999;55(2):366–386. [PubMed]
  • Siest G, Bertrand P, Herbeth B, Vincent-Viry M, Schiele F, Sass C, Visvikis S. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin Chem Lab Med. 2000 Sep;38(9):841–852. [PubMed]
  • Linder MW, Prough RA, Valdes R., Jr Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem. 1997 Feb;43(2):254–266. [PubMed]
  • Zhou HH, Liu ZQ. Ethnic differences in drug metabolism. Clin Chem Lab Med. 2000 Sep;38(9):899–903. [PubMed]
  • Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991 May;20(5):350–373. [PubMed]
  • Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001 May 3;344(18):1351–1357. [PubMed]
  • Lang CC, Stein CM, Brown RM, Deegan R, Nelson R, He HB, Wood M, Wood AJ. Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med. 1995 Jul 20;333(3):155–160. [PubMed]
  • Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–850. [PubMed]
  • Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. QJM. 1999 Apr;92(4):187–192. [PubMed]
  • Baker Emma H, Duggal Ajay, Dong Yanbin, Ireson Nicola J, Wood Monique, Markandu Nirmala D, MacGregor Graham A. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002 Jul;40(1):13–17. [PubMed]
  • Saunders E. Drug treatment considerations for the hypertensive black patient. J Fam Pract. 1988 Jun;26(6):659–664. [PubMed]
  • Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin. 2000;16(2):66–79. [PubMed]
  • Flack JM, Saunders E, Gradman A, Kraus WE, Lester FM, Pratt JH, Alderman M, Green S, Vargas R, Espenshade M, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001 Aug;23(8):1193–1208. [PubMed]
  • Prisant LM, Mensah GA. Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol. 1996 Oct;36(10):867–873. [PubMed]
  • Richardson AD, Piepho RW. Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000 Feb;38(2):75–79. [PubMed]
  • Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 2000 Mar 27;160(6):825–831. [PubMed]
  • Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, Sowers JR, Zemel MB, Curry C, Schoenberger J, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990 Aug;150(8):1707–1713. [PubMed]
  • Saunders E, Curry C, Hinds J, Kong BW, Medakovic M, Poland M, Roper K. Labetalol compared with propranolol in the treatment of black hypertensive patients. J Clin Hypertens. 1987 Sep;3(3):294–302. [PubMed]
  • Townsend RR, DiPette DJ, Goodman R, Blumfield D, Cronin R, Gradman A, Katz LA, McCarthy EP, Sopko G. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther. 1990 Dec;48(6):665–675. [PubMed]
  • Dahlöf Björn, Devereux Richard B, Kjeldsen Sverre E, Julius Stevo, Beevers Gareth, de Faire Ulf, Fyhrquist Frej, Ibsen Hans, Kristiansson Krister, Lederballe-Pedersen Ole, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995–1003. [PubMed]
  • Lindholm Lars H, Ibsen Hans, Dahlöf Björn, Devereux Richard B, Beevers Gareth, de Faire Ulf, Fyhrquist Frej, Julius Stevo, Kjeldsen Sverre E, Kristiansson Krister, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):1004–1010. [PubMed]
  • Chrysant SG, Brown RD, Kem DC, Brown JL. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. Clin Pharmacol Ther. 1983 Jun;33(6):741–746. [PubMed]
  • Goodman C, Rosendorff C, Coull A. Comparison of the antihypertensive effect of enalapril and propranolol in black South Africans. S Afr Med J. 1985 Apr 27;67(17):672–676. [PubMed]
  • Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001 May 3;344(18):1358–1365. [PubMed]
  • Strickland TL, Ranganath V, Lin KM, Poland RE, Mendoza R, Smith MW. Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacol Bull. 1991;27(4):441–448. [PubMed]
  • Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990 Oct;47(10):945–948. [PubMed]
  • Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, Yunis EJ. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1997 Jun 1;89(11):4167–4174. [PubMed]
  • Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269–296. [PubMed]
  • Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982 Sep-Oct;7(5):373–400. [PubMed]
Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association